Bicara Therapeutics Inc. (BCAX)
BCAXNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$10.17
+0.1900 (+1.90%) today
At the close, Nov 10, 4:00 PM ET. After hours $10.17 -0.10%
- Market cap
- $673.64m
- P/E
- –
- EPS, last 4 quarters
- $-3.47
- Dividend yield
- –
- Day range
- $9.44 to $10.32
- 52-week range
- $7.87 to $30.99
- Average volume
- 1.23m
- Previous close
- $9.98
Analysts
9 coveringBuy6 buy, 2 hold, 1 sell
Targets a year out average $30.33, +198.2% from here
Earnings
next estimate $-0.8900Next report
Dec 2025
+5.6%
Mar 2026
-45.3%
Jun 2026
-6.5%
Sep 2026
-23.8%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$40.68m | -$41.12m | -$60.24m | -$59.95m |
| Net income | -$36.33m | -$37.39m | -$56.21m | -$55.44m |
News
8 latest- Bicara (BCAX) Q3 2026 Earnings Call TranscriptThe Motley Fool · 1 day ago
- What Bicara Therapeutics (BCAX) Said on Its Q3 Earnings CallMarketBeat · 1 day ago
- Pliant Therapeutics Names David Raben As CMO To Lead PLN-101095 Development RTTNews · Oct 1, 2026
- Bicara Therapeutics (BCAX) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 18, 2026
- Bicara Therapeutics Q2 Net Loss Expands; Phase 3 FORTIFI-HN01 Study Enrollment On Track RTTNews · Aug 12, 2026
- Bicara Therapeutics Q2 Earnings Call HighlightsMarketBeat · Aug 11, 2026
- What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?The Motley Fool · Jun 13, 2026
- Bicara (BCAX) Q4 2025 Earnings TranscriptThe Motley Fool · Jun 1, 2026
The company
Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of Bicara's lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF- signaling within the tumor microenvironment (TME).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- bicara.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.